Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour

Not Applicable

Completed

• Conditions: Social-benefit; Influenza Vaccine; Self-benefit; Behavioral Intervention
• Interventions: Behavioral: Other-benefit message; Behavioral: Self-benefit message

• Registration Number: NCT04230343
• Lead Sponsor: SB Istanbul Education and Research Hospital

Brief Summary

Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-13
• Primary Completion: 2017-03-25
• Study Completion: 2017-03-25
• Status Verified: 2020-01
• Study First Submitted: 2020-01-12
• Study First Submitted QC: 2020-01-13
• Last Update Submitted: 2020-01-13
• Study First Posted: 2020-01-18
• Last Update Posted: 2020-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 244

Inclusion Criteria

• Patients hospitalized at medical departments of the hospital who are on the day of discharge

Exclusion Criteria

• Egg ellergy
• Previous allergic reaction to influenza vaccine
• Pregnancy
• Cognitive disability

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Social-benefit arm	Other-benefit message	-
Self-benefit arm	Self-benefit message	-

Primary Outcome Measures

Name	Time	Method
Vaccine uptake following the introduction of the pamphlet	On the same day, upto 24 hours	Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.

Secondary Outcome Measures

Name	Time	Method
Vaccine uptake in high and low risk group patients following the introduction of the pamphlet	On the same day, upto 24 hours	Vaccine uptake in high and low risk group patients. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the social-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.

Trial Locations

Locations (1)

SB Istanbul Training and Research Hospital; 🇹🇷 Istanbul, Turkey